PHARMACOECONOMIC EVALUATION OF ABIRATERONE ACETATE VERSUS CABAZITAXEL IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN KAZAKHSTAN

被引：1
|
作者：
Kostyuk, A. [1 ]
Almadiyeva, A. [1 ]
机构：
[1] Natl Ctr Hlth Dev, Astana, Kazakhstan
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.513
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A412 / A412
页数：1
相关论文
共 50 条
  • [41] A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer
    Clayton, Ravinder
    Wu, Jackson
    Heng, Daniel Y.
    North, Scott A.
    Emmenegger, Urban
    Hotte, Sebastien
    Chi, Kim
    Zielinski, Rob
    Al-Shamsi, Humaid
    Chen, Leo
    Eigl, Bernhard
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2014, 8 (9-10): : E583 - E590
  • [42] Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients
    Efstathiou, Eleni
    Titus, Mark
    Wen, Sijin
    Troncoso, Patricia
    Hoang, Anh
    Corn, Paul
    Prokhorova, Ina
    Araujo, John
    Dmuchowski, Carl
    Melhem-Bertrandt, Amal
    Patil, Shiva
    Logothetis, Christopher J.
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (01): : 119 - 127
  • [43] Evaluation of factors predicting response to abiraterone acetate in metastatic castration-resistant prostate cancer: A prospective study
    Kumawat, Ghanshyam
    Yadav, S. S.
    Jaiswal, Sanjeev
    Sahu, Ramdayal
    Garg, Anurag
    Tomar, Vinay
    [J]. JOURNAL OF CLINICAL UROLOGY, 2024, 17 (04) : 386 - 394
  • [44] Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide
    Modena, Alessandra
    Ciccarese, Chiara
    Fantinel, Emanuela
    Bimbatti, Davide
    Tortora, Giampaolo
    Massari, Francesco
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (09) : 1037 - 1048
  • [45] LONG SURVIVAL WITH ABIRATERONE ACETATE IN AN ELDERLY PATIENT WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Macrini, Serena
    Poti, Giulia
    Giacinti, Silvana
    Bassanelli, Maria
    Roberto, Michela
    Aschelter, Anna Maria
    Marchetti, Paolo
    [J]. ANTICANCER RESEARCH, 2017, 37 (04) : 2085 - 2085
  • [46] Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer
    Lesley J. Scott
    [J]. Drugs, 2017, 77 : 1565 - 1576
  • [47] The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate
    Onal, Cem
    Sedef, Ali Murat
    Kose, Fatih
    Oymak, Ezgi
    Guler, Ozan Cem
    Sumbul, Ahmet Taner
    Aksoy, Sercan
    Yildirim, Berna Akkus
    Besen, Ali Ayberk
    Muallaoglu, Sadik
    Mertsoylu, Huseyin
    Ozyigit, Gokhan
    [J]. FUTURE ONCOLOGY, 2019, 15 (13) : 1469 - 1479
  • [48] Erratum to: Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer
    Lesley J. Scott
    Lily P. H. Yang
    Katherine A. Lyseng-Williamson
    [J]. Drugs & Aging, 2012, 29 (3) : 1 - 1
  • [49] Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
    Thomsen, Frederik Birkebaek
    Roder, Martin Andreas
    Rathenborg, Per
    Brasso, Klaus
    Borre, Michael
    Iversen, Peter
    [J]. SCANDINAVIAN JOURNAL OF UROLOGY, 2014, 48 (03) : 268 - 275
  • [50] Abiraterone Acetate in metastatic castration-resistant Prostate Carcinoma: When to begin?
    Miller, Kurt
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 6 - 7
12345